(CercleFinance.com) – Biogen announced on Tuesday that it would exercise an option to participate in the development and commercialization of mosunetuzumab, an experimental blood cancer treatment discovered by Roche.
Under the terms of the agreement, the American biopharmaceutical laboratory will pay Genentech, the biotechnology subsidiary of Roche, the sum of 30 million dollars as part of their collaboration agreement.
Mosunetuzumab is a bispecific antibody that has shown activity
encouraging against several types of blood cancer, such as non-Hodgkin’s lymphoma.
In June 2020, the FDA granted the drug breakthrough therapy status for the treatment of follicular lymphoma.
Copyright © 2022 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
